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Abstract
Hypertrophic cardiomyopathy (HCM) is the most frequent genetic cardiac disease with a
prevalence of 1:500 to 1:200. While most patients show obstructive HCM and a relatively sta-
ble clinical phenotype (stage II), a small group of patients progresses to end-stage HCM
(stage IV) within a relatively brief period. Previous research has shown sex-differences in
stage II HCM with more diastolic dysfunction in female than in male patients. Moreover,
female patients more often show progression to heart failure. Here we investigated if differ-
ences in functional and structural properties of the heart may underlie sex-differences in dis-
ease progression from stage II to stage IV HCM. Cardiac tissue from stage II and IV patients
was obtained during myectomy (n = 54) and heart transplantation (n = 10), respectively. Iso-
metric force was measured in membrane-permeabilized cardiomyocytes to define active and
passive myofilament force development. Titin isoform composition was assessed using gel
electrophoresis, and the amount of fibrosis and capillary density were determined with histol-
ogy. In accordance with disease stage-dependent adverse cardiac remodeling end-stage
patients showed a thinner interventricular septal wall and larger left ventricular and atrial
diameters compared to stage II patients. Cardiomyocyte contractile properties and fibrosis
were comparable between stage II and IV, while capillary density was significantly lower in
stage IV compared to stage II. Women showed more adverse cellular remodeling compared
to men at stage II, evident from more compliant titin, more fibrosis and lower capillary density.
However, the disease stage-dependent reduction in capillary density was largest in men. In
conclusion, the more severe cellular remodeling in female compared to male stage II patients
suggests a more advanced disease stage at the time of myectomy in women. Changes in
cardiomyocyte contractile properties do not explain the progression of stage II to stage IV,
while reduced capillary density may underlie disease progression to end-stage heart failure.
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Introduction
Hypertrophic cardiomyopathy (HCM) is the most prevalent genetic cardiac disease occurring
in 2–5 per 1000 individuals, and is caused by mutations in genes encoding sarcomeric pro-
teins.[1–3] The defining feature of HCM is unexplained left ventricular (LV) hypertrophy that
mainly affects the interventricular septum (IVS). In addition to hypertrophy, the diseased
myocardium is characterized by increased interstitial fibrosis, myofibrillar and cardiomyocyte
disarray and vascular abnormalities.[4,5] Clinical symptoms generally appear between 20–50
years of age and can range from shortness of breath to atrial fibrillation. In the majority of
patients, these symptoms can be managed with therapy, and individuals have a normal life
expectancy.[6] However, a subset of patients suffers from life-threatening complications such
as sudden cardiac arrest at a young age or progresses to end-stage heart failure.[6]
To classify the different forms of HCM, Olivotto et al.[7] described different stages in car-
diac disease progression ranging from unaffected mutation carriers to end-stage failing HCM
patients.[8] The majority of HCM patients develop a ‘classic’ (stage II) form of HCM with the
characteristic septal thickening, LV outflow tract obstruction (LVOTO) and diastolic dysfunc-
tion. Approximately 5–10% of all HCM patients progress to the severe end-stage of HCM
(stage IV), which is characterized by thinning of the IVS and LV wall, and left atrial dilation,
extensive fibrosis and impaired systolic function. These patients show a decrease in NYHA
classification and are often diagnosed with or develop atrial fibrillation.[9] The progression
from the ‘classic’ stage of HCM, via adverse remodeling (stage III) to stage IV shows a rela-
tively short clinical course of approximately 6.5 years.[10] It is unclear which factors underlie
the transition from a stable stage II to stage IV of HCM in a relatively small but severely ill
group of patients.
Notably, the lifetime risk of heart failure is higher in women than in men.[11] At first evalu-
ation, female HCM patients are older and present more often with symptoms.[12,13] More-
over, women show a higher risk of progression to heart failure (stage IV).[12,14] We recently
showed more severe diastolic dysfunction in female compared to male HCM patients at the
time of myectomy (stage II), which coincided with more advanced tissue remodeling in
women compared to men.[15] Here we investigated if differences in functional and structural
properties of the heart may underlie sex-differences in disease progression from stage II to IV
of HCM. Functional measurements in single cardiomyocytes were combined with analyses of
protein expression, fibrosis and capillary density.
Methods
Myocardial samples
Cardiac samples were collected from 54 patients with obstructive HCM (stage II) (44% female)
carrying a MYH7 (myosin heavy chain; n = 14) or a MYBPC3 (myosin-binding protein-C;
n = 40) mutation (stage II) and 10 end-stage (stage IV) patients (40% female) carrying a
MYH7 (n = 6), a MYBPC3 (n = 3) or a TNNT2 (troponin T; n = 1) mutation. Fig 1A illustrates
the different gene mutations and Fig 1B shows where mutations are located in the protein.
Table 1 provides an overview of the gene mutations of all patients. Patient samples were com-
pared with non-failing control samples (n = 30; 40±14 years; 43% female; S1 Table) without a
history of cardiac abnormalities. IVS tissue from the stage II HCM group was collected during
myectomy to relieve LVOTO. Cardiac tissue from stage IV HCM was obtained during heart
transplantation surgery and consisted of IVS (n = 6) and LV tissue (n = 4). Control samples
included IVS (n = 3) and LV (n = 27) tissue. All samples were immediately frozen and stored
in liquid nitrogen. This study was approved by the local ethics board of the Erasmus Medical
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Center (protocol number MEC-2010-40) and written informed consent of patients was
obtained. Non-failing donor samples were acquired from the University of Sydney, Australia,
with the ethical approval of the Human Research Ethics Committee (#2012/2814). We
acknowledge the uneven distribution between patient numbers and mutations and tissue loca-
tions (IVS and LV). However, our tissue characterization was dependent on available cardiac
tissue and clinical parameters. Due to limited tissue availability, not all analyses could be per-
formed in all patient/control samples.
Echocardiographic measurements
Echocardiographic studies were done with commercially available systems and analyzed
according to the American Society of Echocardiography guidelines.[16] Maximal wall thick-
ness, left atrial diameter (LAD), LV end-diastolic diameter (LVEDD), and LVOTO gradient
were measured. LVOTO was defined as a gradient� 30 mmHg at rest or during provocation.
Mitral valve inflow was recorded using pulsed wave Doppler from the apical four chamber
view. Mitral E and A velocity (cm/s) and deceleration time (ms) were measured. Pulsed wave
tissue Doppler imaging was used to measure septal e’ velocity (cm/s). Continuous wave Dopp-
ler in the parasternal and apical four chamber was used to measure tricuspid regurgitation
(TR) velocity (m/s). Echocardiographic data and medication are shown in Table 1. For the
end-stage HCM group, a limited set of echocardiographic data was obtained, and not all
parameters were obtained for stage II patients.
Diastolic dysfunction was graded as follows: grade I when E/A ratio� 0.8 and E peak
velocity� 50 cm/s; grade III when E/A ratio� 2. In patients with E/A ratio� 0.8 and E peak
velocity > 50 cm/s or E/A ratio > 0.8 but< 2, the E/e’ ratio (>14), LADi (>24) and TR veloc-
ity (> 2.8 m/s) were used to further differentiate diastolic function. When� 2 out of 3 vari-
ables were abnormal, LA pressure was elevated and grade II diastolic dysfunction was present.
When 1 out of 3 variables was abnormal, grade I diastolic dysfunction was present.[17]
Isometric force measurements
Force measurements were performed in mechanically isolated single, membrane-permeabi-
lized, cardiomyocytes as described previously.[18,19] In short, we measured passive tension at
a range of sarcomere lengths (SL)(1.8–2.4 μm). All passive forces were normalized to cardio-
myocyte cross-sectional area (CSA) (i.e. CSA = width x depth x π/4). Active tension (maximal
force) was measured at SL 2.2 μm, and we determined myofilament calcium sensitivity (EC50)
by activating cardiomyocytes in solutions with different calcium concentrations.
Protein analyses
Titin isoform gel electrophoresis was performed as previously described.[19,20] Samples were
measured in triplicate, of which the mean was used.
Fig 1. A. Mutations present in the patient samples. Mutations of patients that were included in this study. Myosin heavy chain gene (MYH7) mutations are
depicted in blue squares of which two mutations (R719W and R403Q) were present in both stage II and IV (end-stage) HCM patient groups. Myosin-binding
protein-C gene (MYBPC3) mutations are depicted in the yellow squares of which one mutation (E258K) was present in both HCM patient groups. The three
Dutch founder mutations are depicted in the dotted squares. The troponin T gene (TNNT2) mutation is depicted in the green square and was only present in
the end-stage patient group. Color tone indicates the number of patients carrying the specific mutation, with the darkest tone representing most patients
(patient details are given in Table 1). B. Mutation location. Schematic of 3 main HCM sarcomere proteins: myosin heavy chain in green (Myosin), cardiac
myosin-binding protein-C in purple (cMyBP-C) and cardiac troponin T in orange (cTnT). The location of the mutations is indicated with the blue circles (M).
The letters N and C stand for the N-terminus and C-terminus respectively. The numbers indicate the amino acids of the sarcomere proteins.
https://doi.org/10.1371/journal.pone.0232427.g001
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Table 1. Patient information and gene mutations.
Sample
code
SEX AGE
(Y)
GENE MUTATION
CODE
DOMAIN &
INFO
IVS
(mm)
IVSi LAD LADi LVEDD LVEDDi LVOTO E/A
RATIO
E
WAVE
TR
VELOCITY
DRUG
REGIMEN
STAGE II
HCM 2 F 32 MYBPC3 Y842L C6 / DF 30 20 - - 40 27 - - - 0.3 Bb
HCM 3 F 39 MYPBC3 Y842L C6 / DF 20 11 40 23 38 21 49 - 0.8 - Ccb, diuretics
HCM 4 F 44 MYBPC3 Y842L C6 / DF 20 13 45 30 40 27 94 - 0.8 - Ccb
HCM 5 F 41 MYBPC3 c.1458-1G>C Intr 16 22 13 46 27 37 21 92 3.8 1.1 - Bb, ccb
HCM 7 F 44 MYBPC3 Y842L C6 / DF 17 11 40 25 42 26 - - - Ccb
HCM 26 F 57 MYBPC3 Y842L C6 / DF 24 11 62 28 41 18 74 0.7 0.4 - Bb
HCM 34 F 47 MYBPC3 R597Q C4 20 10 46 23 42 21 38 2 0.9 3 Bb, ccb, statin
HCM 35 F 65 MYBPC3 A536A C3 19 - - - 45 - 18 - - 2.7 Bb, ccb
HCM 52 F 24 MYBPC3 R943x C7 / DF 24 14 44 26 35 20 34 1.12 0.9 2.5 Bb
HCM 60 F 45 MYBPC3 c.3029delA C8 18 9 46 24 42 22 125 0.68 0.6 1.9 Bb, ccb
HCM 94 F 66 MYBPC3 E611K C4 15 8 53 27 43 22 55 - - 2 Bb, ccb, ACE,
statin, oac
HCM 113 F 21 MYBPC3 R943x C7 / DF 45 28 43 26 40 25 27 1.26 0.7 2.3 Bb, ccb
HCM 116 F 53 MYBPC3 R943x C7 / DF - - - - - - - - - - -
HCM 121 F 54 MYBPC3 Q1259R C10 20 12 33 21 37 23 45 0.93 1 1.5 Ccb
HCM 123 F 59 MYBPC3 Y842L C6 / DF 21 - 45 - 55 - 64 1.2 1.4 3.1 Bb, ccb, oac,
ACE,
Diuretics
HCM 180 F 51 MYBPC3 Y340x MM 32 - - - 45 - 70 2.25 0.9 - Bb
HCM 148 F 51 MYBPC3 G531R C3 20 9 58 26 51 23 56 0.97 0.7 - -
HCM 150 F 57 MYBPC3 P699Q C5 24 12 49 25 50 26 68 2.5 1.3 - -
HCM 12 M 37 MYBPC3 c.927-2A>G Intr 11 19 9 41 20 42 21 44 2 1 - Bb
HCM 33 M 48 MYBPC3 c.927-2A>G Intr 11 - - - - - - 82 - - - Bb
HCM 36 M 22 MYBPC3 c.927-2A>G Intr 11 30 - 60 - 44 - 71 0.73 0.4 - Bb, ccb
HCM 42 M 32 MYBPC3 Y842L C6 / DF 23 13 47 26 43 24 64 1.03 0.7 - Bb, ccb
HCM 43 M 60 MYBPC3 Y842L C6 / DF 23 - 52 - 45 - 77 2 0.8 - Bb, ccb
HCM 47 M 55 MYBPC3 Y1136d C9 25 13 - - 40 21 96 1.57 1 2.9 Ccb
HCM 62 M 36 MYBPC3 E258K MM 27 14 37 19 32 16 - 1.21 0.4 1.8 Bb, ACE,
diuretics
HCM 63 M 33 MYBPC3 R943x C7 / DF 21 12 40 22 46 26 25 2.38 1.1 - Bb, ccb
HCM 66 M 45 MYBPC3 Q1259R C10 - - - - - - - - - - -
HCM 71 M 49 MYBPC3 R943x C7 / DF 16 7 47 22 44 20 - 0.78 0.5 2.3 Bb
HCM 82 M 71 MYBPC3 S928L C7 20 11 52 29 49 28 64 0.87 0.7 2.2 Bb, oac
HCM 83 M 17 MYBPC3 Y842L C6 / DF - - - - - - - - - - -
HCM 101 M 20 MYBPC3 c.1458-1G>C Intr 16 38 17 42 19 - - - 1.25 0.5 - Bb
HCM 103 M 26 MYBPC3 Y842L C6 / DF 20 9 47 22 47 22 13 1.33 0.7 1.4 Bb
HCM 104 M 33 MYBPC3 Y842L C6 / DF 24 13 33 18 40 22 31 1.08 0.6 - Bb
HCM 110 M 39 MYBPC3 E334x MM 18 8 - - 46 21 9 2.48 0.8 2.4 Ccb
HCM 120 M 27 MYBPC3 Y842L C6 / DF 24 13 39 21 37 20 61 1.42 0.8 2.3 Bb
HCM 122 M 50 MYBPC3 c.3331-2A>G Intr 30 22 10 - - 45 21 58 0.67 0.7 2.5 Bb, ccb
HCM 124 M 53 MYBPC3 R943x C7 / DF 21 10 43 21 47 23 41 0.64 0.5 2.2 Bb
HCM 133 M 58 MYBPC3 G148R PA 21 10 44 21 40 19 19 0.86 0.6 2.4 Bb, statin, oac
HCM 141 M 46 MYBPC3 E258K MM 23 - 51 - 51 - 20 1.22 0.7 - Bb
HCM 149 M 46 MYBPC3 E258K MM 26 - - - - - 72 - - - -
HCM 27 F 58 MYH7 T1377M MT 20 13 48 30 - - 100 - 0.6 2.8 Bb
HCM 42B F 46 MYH7 V606M MH 20 9 51 24 - - 77 3.38 0.8 2.6 Bb, ccb
HCM 157 F 65 MYH7 S1843C MT 22 10 58 27 42 20 - 2.37 1.9 3.3 Ccb, statin
HCM 166 F 66 MYH7 R694C MH 16 - 41 - - - 41 0.79 1.1 - Bb, ccb, ASA
HCM 144 F 30 MYH7 S782R Hinge 29 - - - 42 - 128 - - - -
HCM 154 F 6 MYH7 R719W MH / Fam I 20 26 - - - - 46 - - - -
HCM 32 M 43 MYH7 T1377M MT 21 9 51 21 47 19 121 1 0.6 - Bb, diuretics
HCM 80 M 34 MYH7 c.1291G>C MT 17 8 - - 45 21 85 1.45 0.9 1.4 Bb, ccb
(Continued)
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Histomorphometrical analyses
Cardiomyocyte myofibril density (MFD) was measured using Electron Microscopy (EM) as
described previously.[21] MFD was calculated by the sum of myofibril area relative to the total
cardiomyocyte area and expressed as a percentage.[21,22] To determine the extent of intersti-
tial and replacement fibrosis, cryosections were stained using Picro-Sirius Red, and fibrosis
was expressed as collagen volume fraction (CVF%). Capillary density was determined by the
number of capillaries per mm2 and per cardiomyocyte. Cryosections were incubated with a
primary antibody (Monoclonal Mouse anti-Human CD31, Endothelial cell; Clone JC70A;
DAKO; REF M0823) and secondary antibody (EnVision HRP α-mouse/rabbit (DAKO). Stain-
ing was visualized using 3.3’-diaminobenzidine (0.1 mg/mL, 0.02% H2O2), the sections were
subsequently counterstained with hematoxylin.
Table 1. (Continued)
Sample
code
SEX AGE
(Y)
GENE MUTATION
CODE
DOMAIN &
INFO
IVS
(mm)
IVSi LAD LADi LVEDD LVEDDi LVOTO E/A
RATIO
E
WAVE
TR
VELOCITY
DRUG
REGIMEN
HCM 106 M 35 MYH7 D928V MT 16 8 - - 47 24 16 0.93 0.8 2.1 Bb
HCM 114 M 69 MYH7 A326P MH 19 - 43 - 33 - 71 0.6 0.6 2.1 Bb, statin,
ASA
HCM 119 M 41 MYH7 E1233K MT 20 9 56 26 - - 81 1.26 1.1 1.4 Bb
HCM 130 M 45 MYH7 A326P MH 18 9 42 21 50 25 27 2.6 1.3 3.3 Bb, statin,
noac
HCM 145 M 28 MYH7 R694C MH 42 - 52 - 38 - 30 1.5 0.6 - Bb
HCM 143 M 26 MYH7 R403Q MH 34 - - - 50 - 85 - - - -
MEAN
STAGE II
23±6 12
±4
47±7 24±3 43±5 22±3 59±30 1.75
±0.5
1±0 2.5±0.7
STAGE
IV
HCM 147 F 36 MYBPC3 P955R C7 / DF - - - - 75 - - - - - -
HCM 142 M 46 MYPBC3 E258K
+ E441K
MM + C2 18 - 51 - 50 - 5 - - - Bb, ACE,
diuretics
HCM 137 M 54 MYBPC3 Y842L C6 - - - - 60 - - - - - -
HCM 183 F 39 MYH7 R453C MH - - - - 54 31 10 - - - -
HCM 151 F 59 MYH7 R403Q MH - - 70 50 53 38 10 - - - -
HCM 181 F 40 MYH7 R719W MH / Fam I 18 10 48 27 54 31 - - - - -
HCM 152 M 35 MYH7 R403Q MH - - - - - - - - - - -
HCM 153 M 49 MYH7 R719W MH / Fam I 16 9 52 29 50 28 - - - - -
HCM 139 M 61 MYH7 R787H Hinge - - - - 58 - - - - - -
HCM
140A
M 26 TNNT2 K280N C-terminus - - - - - - - - - - -
MEAN
STAGE
IV
17±1 10
+1
55
+10
35
+13
57±8 32±4 8±3
Abbreviations: F, female; M, male; sarcomere genes MYBPC3, MYH7 and TNNT2 encoding myosin-binding protein-C, myosin heavy chain and cardiac troponin T,
respectively. Domain & info: DF: Dutch founder mutation; Fam I: patient samples part of one family. Domain locations of the mutations (also illustrated in Fig 1B):
MM: cMyBP-C motif (in Fig 1B depicted as yellow stripes between C1-C2); PA: Pro-Ala rich region (in Fig 1B depicted as grey stripes between C0-C1); MT: Myosin tail
(in Fig 1B the dark green line); MH: Myosin head; Hinge: hinge region of myosin (in Fig 1B depicted as the curled green line); IVS, interventricular septum; IVSi, IVS
indexed by body surface area (BSA); LAD, left atrial diameter; LADi, LAD indexed by BSA; LVEDD, left ventricular end-diastolic diameter; LVEDDi indexed by BSA;
LVOTO, left ventricular outflow tract obstruction; E/A ratio, ratio of mitral valve early (E) and late (A) velocity; E wave, mitral valve early velocity (cm/s); TR velocity,
tricuspid regurgitation velocity (m/s); bb, betablocker; ccb, calcium channel blocker; ACE, ACE-inhibitor; (N)OAC, (novel) oral anticoagulant; ASA, antiplatelet therapy
(acetylsalicylic acid).
https://doi.org/10.1371/journal.pone.0232427.t001
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Data analyses
Data in figures are presented as mean±standard error of the mean per group, data in tables is
presented as mean±standard deviation. If data was normally distributed means were compared
with a student’s T-test, a Mann-Whitney test was used when data was not normally distrib-
uted. Sex-differences were tested with a 2-way ANOVA. P<0.05 was considered significant,
differences to controls are indicated by an asterisk (�), sex-differences are indicated by a hash-
tag (#).
Results
A MYBPC3 gene mutation was present in 43 patients (40 stage II and 3 stage IV), of which 18
were founder mutations. Most MYH7 mutations were located in the myosin head (60%) (Fig
1B and Table 1). Average values for echocardiographic characteristics of HCM stage II and IV
patients are shown in Table 2. HCM stage II and IV patients have a similar average age and
male patients are dominant in both groups. All patients meet the diagnostic criteria of an IVS
thickness> 15 mm (Table 1), however, the HCM stage II patients show significantly greater
septal thickness than the HCM stage IV patients. This is in line with a higher LVOTO in the
stage II compared to stage IV HCM. LAD and LVEDD were significantly higher in stage IV
compared to stage II HCM.[23] All stage IV patients were given grade III diastolic dysfunction,
while stage II patients included 29% with grade III, 29% with grade II and 42% with grade I
diastolic dysfunction. Female stage II patients show more severe diastolic dysfunction com-
pared to male patients: 86% grade II or III diastolic dysfunction in women compared to 42%
grade II in men. Drug regimen was different between female and male stage II HCM patients:
80% of the men received betablockers in contrast to 58% of the women. Calcium channel
blockers were prescribed more frequently to women compared to men (58% versus 27%,
respectively; Table 1). Unfortunately we could only retrieve drug regimen of one of our stage
IV patients.
Maximal force generating capacity (Fmax) of cardiomyocytes was significantly lower in
stage II and IV HCM compared to controls (21.8±1.7 and 19.6±2.3 versus 32.8±2.9 KN/m2
respectively; p<0.01), but did not differ between patient groups or sex (Fig 2A). Passive ten-
sion (Fpass) was lower in both stage II and IV HCM compared to controls (Fig 2B; p<0.0001).
No sex-differences in passive tension were observed. Fig 2C shows representative images of
myofibril density analyses by EM (stage II and IV HCM patient samples). Both HCM groups
showed a similar decrease in MFD compared to controls (p<0.0001), while no sex-difference
was observed (Fig 2D). Compared to controls, a significantly higher myofilament calcium-
Table 2. Clinical characteristics of HCM stage II and IV patient groups.
stage II stage IV P
N (% female) 54 (44%) 10 (40%)
Age (years) 43.4±14.7 44.5±11.3 0.83
IVS (mm) 22.9±6.3 17.3±1.2 <0.05
LVOTO (mmHG) 59.2±30.4 8.3±2.9 <0.001
LAD (mm) 46.5±6.9 55.3±10.0 <0.05
LVEDD (mm) 43.1±5.0 56.8±8.2 <0.0001
Abbreviations: IVS (interventricular septum); LAD (left atrial dimension); LVEDD (left ventricular end-diastolic
dimension); LVOTO (left ventricular outflow tract obstruction).
https://doi.org/10.1371/journal.pone.0232427.t002
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sensitivity was found in both stage II and IV HCM (EC50: 2.2±0.1 μmol/L and 3.0±0.2 versus
2.0±0.1 respectively; p<0.001), with no difference between the HCM groups or sex (Fig 2E).
The N2BA/N2B titin isoform ratio was significantly higher in both HCM groups compared
to controls, without a difference between stage II and IV HCM (0.84±0.05 versus 0.81±0.12).
At both HCM disease stages females show a higher N2BA/N2B ratio compared to males (Fig
3A). Analysis of fibrosis showed increased fibrosis in stage II and IV HCM patients compared
to controls (4.6±0.5 and 5.5±0.9 versus 1.2±0.2% respectively; p<0.001). Representative Picro-
Sirius red staining images of stage II and IV HCM are shown in Fig 3C. There was no differ-
ence between the HCM groups, however, in both disease stages women showed significantly
more fibrosis than men (Fig 3B). We found significant correlations between the degree of dia-
stolic dysfunction and titin isoform composition (Fig 3D; R2: 0.13; p<0.05) and the amount of
fibrosis (Fig 3E; R2: 0.31; p<0.01).
Fig 4A shows images of capillary staining in a stage II and IV HCM sample. Capillary den-
sity is depicted as capillaries per mm2 (Fig 4B) as well as per cardiomyocyte (Fig 4C). Capillary
density is significantly lower in stage II and IV HCM patients compared to controls (Fig 4B
and 4C; p<0.0001). Furthermore, both methods showed a lower capillary density in stage IV
compared to stage II HCM patients (p<0.05). Capillary density in stage II HCM is significantly
lower in women compared to men (p<0.05). Interestingly, the reduction in capillary density
from stage II to stage IV is attributed to the reduction of capillary density in male to a similar
level as observed in female HCM patients.
Fig 2. Cardiomyocyte properties–no differences between stage II and IV HCM patients. A) Maximal force development is lower in stage II (n = 26)
and stage IV (n = 8) patients in comparison to controls (p<0.0001) and no sex-differences were found. B) Passive tension is lower in stage II (n = 19)
and stage IV (n = 8) patients in comparison to controls (p<0.0001, no sex-differences were found). C and D) Electron Microscopy (EM) imaging was
performed and showed reduced myofibril density in stage II and IV HCM patient samples compared to controls. No sex-difference was present in
myofibril density. E) Myofilament calcium-sensitivity is depicted as EC50 (the amount of calcium needed to reach 50% of maximal force). EC50 is
significantly lower in stage II and IV HCM patients compared to controls (p<0.001). No sex-differences were found. Controls used for passive tension:
1, 12–13, 20; maximal force development: 5–8, 11–12, 15–16, 18–19, 23, 26; myofilament calcium-sensitivity: 5–8, 11–12, 15–16, 18–19, 23.
https://doi.org/10.1371/journal.pone.0232427.g002
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Discussion
We investigated if cardiac tissue properties were more severely affected at stage IV (end-stage)
than stage II of HCM, and whether these properties change in a sex-specific manner. The
main findings of our study are: 1) Changes in (functional) myofilament properties of cardio-
myocytes are similar in stage II and stage IV HCM; 2) A similar increase in fibrosis compared
to controls is present at stage II and IV HCM; 3) Capillary density is significantly lower at
stage IV compared to stage II HCM; 4) Sex-specific differences in HCM are marked by higher
levels of fibrosis, a larger shift to compliant titin isoform and a lower capillary density in female
compared to male patients; 5) The disease-stage specific decrease in capillary density is largely
explained by the lower capillary density in men at stage IV compared to stage II. Overall, our
study indicates that loss of capillary density may be a factor underlying disease progression
from stage II to IV in HCM.
Age at time of operation (myectomy or heart transplantation) did not differ between the
two HCM groups and is in line with previous studies.[10,24,25] HCM onset at a young age is
one of the risk factors for developing stage IV HCM. Furthermore, HCM patients that progress
to stage IV more often experience atrial fibrillation, mitral valve regurgitation, more symptom
progression and less LVOTO.[24,26] Many stage IV patients did not have surgical myectomy
Fig 3. Titin and Fibrosis–Female patients show more complaint titin isoform and fibrosis than male patients. A) Diseased hearts (n = 42) show an increase in titin
N2BA/N2B ratio compared to controls (p<0.05). The difference in titin composition is mainly attributed to the female patients, who show an increase in compliant titin
compared to male patients (p<0.05) and compared to controls (p<0.01)(no sex-difference in N2BA/N2B ratio was present in the control group). B) Representative
Picro-Sirius red stainings of HCM stage II and IV patient samples. C) The amount of fibrosis is depicted as collagen volume fraction (CVF). In comparison to controls,
fibrosis is increased in the diseased hearts (stage II (n = 29) and stage IV HCM (n = 8), p<0.001). Female patients show higher levels of fibrosis compared to male
patients (p<0.05). Significant correlations were found between the N2BA/N2B ratio and grade of diastolic dysfunction (p<0.05; panel E), and fibrosis and diastolic
function (p<0.05; panel F). Blue dots and squares depict stage IV HCM patients. Controls used for titin isoform analysis: 1–3, 5–6, 8, 10, 13–14, 16, 20, 22, 24, 26–27.
Controls used for the amount of fibrosis: 4, 8–10, 21, 23, 26, 29–30.
https://doi.org/10.1371/journal.pone.0232427.g003
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before heart transplantation, probably due to the lower frequency of LVOTO in these patients.
[24] Because stage IV patients reach phase II of HCM at a younger age and progress faster,
their age at heart transplantation is similar to HCM patients who undergo surgical myectomy.
As expected, cardiac remodeling was different between stage II and IV HCM patients
(Table 2). Stage IV patients show less hypertrophy of the IVS and increased dimensions of
both LV and left atrium.[8] Both our patient groups showed a predominance of the male sex
(stage II: 56% and stage IV: 60%) which is in line with earlier research (ranging from 55–72%
in end-stage HCM).[25–30] As for stage II HCM patients, based on our recent study, we have
proposed that women may be diagnosed too late because the cut-off value for IVS is not cor-
rected by body surface area.[15] The latter may partly explain the predominance of male
patients in our HCM groups. Interestingly we did find a difference in drug regimen between
stage II women and men. The most prescribed drugs in both genders were betablockers, cal-
cium channel blockers or a combination of both. Men were commonly prescribed betablock-
ers (80% in men versus 58% in women), while women were more frequently prescribed
calcium channel blockers (58% versus 27%) and dual therapy (38% versus 20%).
Fig 4. Capillary density–decreased capillary density in HCM patients. A) Representative CD31 staining of HCM stage II and
IV samples are shown. B) Capillary density is depicted as the number of capillaries per mm2. Capillary density is decreased in
HCM stage II (n = 22) and stage IV (n = 8) compared to controls (p<0.0001). The change in capillary density is sex-dependent.
Female patients show lower capillary density compared to male patients (p<0.05). C) Capillary density is depicted as the
number of capillaries per cardiomyocyte. Capillary density is decreased in HCM patients compared to controls (p<0.05).
Capillary density is significantly decreased in stage IV compared to stage II male patients (p<0.05). Blue dots and squares
represent stage IV HCM patients. Controls used for capillary density: 8–9, 21, 23, 25–26, 29–30.
https://doi.org/10.1371/journal.pone.0232427.g004
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The main difference identified between early and end-stage HCM patient groups was the
larger reduction in capillary density in stage IV compared to stage II. It is known that myocar-
dial blood flow is decreased in HCM patients, with greatest impairments seen during hyper-
emic circumstances.[31] The IVS and sub-endocardial layers are particularly hypo perfused.
[32,33] Importantly, reduced myocardial blood flow has been associated with fibrotic areas of
the myocardium.[32] Chronic exposure to ischemia, whether due to coronary occlusion or the
inability to properly vascularize the hypertrophied myocardium (decreased capillary density),
[5,34] leads to necrosis, massive fibrosis and eventually wall thinning.[26,35] Microvascular
dysfunction in HCM patients was associated with a higher incidence of end-stage heart failure.
[32,36] The lower capillary density in stage IV compared to stage II HCM patients indicates
that reduced coronary perfusion plays a role in disease progression from HCM to end-stage
heart failure.
We are the first to report a sex-difference in capillary density in stage II HCM patients,
where woman have lower capillary density compared to men. Previous reports that analyzed
capillary density have found no influence of sex but were not performed in HCM patients.[37–
41] A recent study showed a correlation between microvascular density and fibrosis, in which
a decrease in capillary density was correlated with an increase in fibrosis.[37] Furthermore,
parameters of diastolic dysfunction were negatively associated with microvascular density.[37]
Interestingly, a significant decrease in capillary density was found only in male patients
between HCM stage II and IV. Capillary density in men with stage IV HCM decreased to the
level of women with HCM. It has been reported that myocardial blood flow in women at rest
is higher compared to men, while the flow reserve (ie. increase in myocardial blood flow
between rest and stress) is lower in women.[42–44] In addition, a correlation was found
between myocardial blood flow and diastolic dysfunction in women.[42] Furthermore, endo-
thelial cell response may be impaired and contribute to HCM disease progression. Future stud-
ies are warranted to define the cellular components which underlie perturbations in
myocardial blood flow during HCM disease progression.
Titin is known to modulate passive stiffness of the cardiomyocyte in an isoform-dependent
manner as it functions as a molecular spring.[32] The heart consists of two isoforms, a short
and stiff N2B isoform and a longer more compliant N2BA isoform. Titin-based stiffness can
therefore be displayed as the N2BA/N2B isoform ratio. Our previous study[15] showed a larger
shift to more compliant titin isoform in female compared to male stage II HCM patients, which
coincided with a higher level of fibrosis. This is in line with the suggestion that the increased
titin compliance might be an attempt to compensate for the increased fibrosis and diastolic dys-
function. Our current study shows that titin isoform composition is not altered during disease
progression as a similar pattern is seen at stage IV HCM (Fig 3A). In accordance, the passive
force measurement curves of both HCM groups clearly overlap (Fig 2B), indicating that passive
properties of myofilaments are not altered during HCM disease progression.
All of our patients that underwent myectomy were labeled as stage II HCM. Our previous
and current study indicate that tissue remodeling is more advanced in women than in men at
an earlier (stage II) disease stage, i.e. more fibrosis, a change in titin isoform composition and a
reduction in capillary density. Based on our observations, our HCM stage II women may actu-
ally be at a more advanced disease stage and may be in need of a more aggressive treatment.
Clinical perspectives and relevance
What is new?
Since no differences were observed in cardiomyocyte contractile properties between early and
advanced stage of HCM, our study points to microvascular ischemia and fibrosis as main
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mechanisms of disease progression rather than cardiomyocyte dysfunction. This suggests that
similar molecular therapeutic targets may be at play in all phases of HCM within the myocar-
dium, and that the different clinical profiles are mostly due to extra-cardiomyocyte variations.
What are the clinical implications?
Analyses of coronary perfusion may be warranted in HCM patients who show a reduction in
IVS during regular clinical check-ups to identify HCM patients at risk to develop end-stage
heart failure.
Translational outlook
Capillary density is only one component of microvascular dysfunction, together with loss of
small vessel vasodilatory function and vessel compression due to increased wall stress. Future
research could focus on evidence of ischemia and clinical research regarding small vessel
function.
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